Profile data is unavailable for this security.
About the company
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
- Revenue in USD (TTM)0.00
- Net income in USD-52.90m
- Incorporated2006
- Employees28.00
- LocationProtara Therapeutics Inc345 Park Avenue South, 3Rd FloorNEW YORK 10010United StatesUSA
- Phone+1 (646) 844-0337
- Fax+1 (302) 655-5049
- Websitehttps://protaratx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CytoDyn Inc | 0.00 | -40.35m | 293.46m | 13.00 | -- | -- | -- | -- | -0.0322 | -0.0322 | 0.00 | -0.0946 | 0.00 | -- | -- | 0.00 | -229.87 | -225.45 | -- | -- | -- | -- | -- | -184,742.10 | -- | -6.09 | -- | -- | -- | -- | 104.41 | -- | -- | -- |
| TriSalus Life Sciences Inc | 40.21m | -72.25m | 295.47m | 110.00 | -- | -- | -- | 7.35 | -2.02 | -2.02 | 1.22 | -0.5357 | 1.26 | 1.76 | 8.11 | 365,518.20 | -123.81 | -- | -183.62 | -- | 84.04 | -- | -98.45 | -- | 2.75 | -6.61 | 5.43 | -- | 58.99 | -- | 47.75 | -- | -- | -- |
| Rezolute Inc | 0.00 | -84.23m | 295.71m | 71.00 | -- | 2.31 | -- | -- | -0.9239 | -0.9239 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -67.21 | -47.11 | -73.08 | -49.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.70 | -- | -- | -- |
| Minerva Neurosciences Inc | 0.00 | -14.03m | 296.86m | 8.00 | -- | -- | -- | -- | -1.85 | -1.85 | 0.00 | -4.94 | 0.00 | -- | -- | 0.00 | -39.57 | -35.73 | -44.01 | -37.64 | -- | -- | -- | -263.85 | -- | -- | 2.36 | -- | -- | -- | 104.80 | -- | -- | -- |
| Amarin Corporation PLC | 226.73m | -86.19m | 298.38m | 275.00 | -- | 0.0325 | -- | 1.32 | -76.48 | -76.48 | 37.99 | 441.28 | 0.3215 | 0.4998 | 1.89 | 824,487.30 | -12.22 | -5.67 | -16.79 | -8.23 | 54.96 | 72.68 | -38.01 | -12.24 | 2.43 | -- | 0.00 | -- | -25.51 | -11.86 | -39.03 | -- | -- | -- |
| Nautilus Biotechnology Inc | 0.00 | -62.81m | 305.02m | 124.00 | -- | 1.80 | -- | -- | -0.4982 | -0.4982 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -27.27 | -20.34 | -28.36 | -20.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.16 | -- | 18.04 | -- |
| Aldeyra Therapeutics Inc | 0.00 | -33.85m | 307.53m | 8.00 | -- | 6.95 | -- | -- | -0.5637 | -0.5637 | 0.00 | 0.7355 | 0.00 | -- | -- | 0.00 | -38.32 | -33.16 | -51.97 | -37.60 | -- | -- | -- | -- | -- | -- | 0.2563 | -- | -- | -- | 39.40 | -- | -- | -- |
| Crescent Biopharma Inc | 0.00 | -55.96m | 308.36m | 4.00 | -- | 1.38 | -- | -- | -21.97 | -21.97 | 0.00 | 8.40 | 0.00 | -- | -- | 0.00 | -72.70 | -55.66 | -86.54 | -62.83 | -- | -- | -- | -2,068.09 | -- | -- | 0.00 | -- | -100.00 | -- | -2.66 | -- | -41.45 | -- |
| Cabaletta Bio Inc | 0.00 | -158.52m | 312.86m | 148.00 | -- | 2.24 | -- | -- | -2.51 | -2.51 | 0.00 | 1.45 | 0.00 | -- | -- | 0.00 | -80.43 | -40.80 | -97.39 | -43.86 | -- | -- | -- | -- | -- | -- | 0.1371 | -- | -- | -- | -71.21 | -- | 26.12 | -- |
| Protara Therapeutics Inc | 0.00 | -52.90m | 317.53m | 28.00 | -- | 1.79 | -- | -- | -1.43 | -1.43 | 0.00 | 3.43 | 0.00 | -- | -- | 0.00 | -44.32 | -35.06 | -48.05 | -36.43 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.33 | -- | 31.54 | -- |
| KALA BIO Inc | 0.00 | -35.84m | 319.60m | 38.00 | -- | -- | -- | -- | -5.94 | -5.94 | 0.00 | -1.17 | 0.00 | -- | -- | 0.00 | -90.62 | -61.19 | -316.35 | -75.37 | -- | -- | -- | -1,732.87 | -- | -12.71 | 1.44 | -- | -- | -- | 8.74 | -- | -31.05 | -- |
| Immuneering Corp | 0.00 | -62.50m | 319.62m | 54.00 | -- | 1.38 | -- | -- | -1.78 | -1.78 | 0.00 | 3.59 | 0.00 | -- | -- | 0.00 | -40.37 | -46.52 | -42.64 | -49.48 | -- | -- | -- | -4,578.95 | -- | -- | 0.00 | -- | -- | -- | -14.15 | -- | 32.83 | -- |
| Foghorn Therapeutics Inc | 24.52m | -72.12m | 323.32m | 112.00 | -- | -- | -- | 13.19 | -1.15 | -1.15 | 0.3896 | -1.59 | 0.0955 | -- | -- | 218,910.70 | -28.10 | -28.66 | -38.84 | -33.19 | -- | -- | -294.16 | -596.97 | -- | -- | -- | -- | -33.83 | -- | 11.99 | -- | -1.32 | -- |
| Sutro Biopharma Inc | 105.65m | -216.77m | 323.72m | 178.00 | -- | -- | -- | 3.06 | -25.98 | -25.98 | 12.61 | -10.25 | 0.3194 | -- | 19.98 | 340,793.60 | -65.54 | -31.36 | -94.60 | -37.63 | -- | -- | -205.18 | -152.29 | -- | -- | -- | -- | -59.64 | 7.74 | -112.99 | -- | -2.30 | -- |
| Neurogene Inc | 0.00 | -85.13m | 340.62m | 107.00 | -- | 1.22 | -- | -- | -4.12 | -4.12 | 0.00 | 17.97 | 0.00 | -- | -- | 0.00 | -37.67 | -27.58 | -40.40 | -29.44 | -- | -- | -- | -28,431.03 | -- | -- | 0.0001 | -- | -- | -- | -106.91 | -- | -1.67 | -- |
| Avalo Therapeutics Inc | 192.00k | -99.70m | 341.83m | 23.00 | -- | 3.67 | -- | 1,780.34 | -8.79 | -8.79 | 0.0169 | 5.14 | 0.0017 | -- | -- | 8,347.83 | -89.35 | -94.60 | -128.95 | -128.31 | 54.69 | 81.11 | -52,019.79 | -790.66 | -- | -9.83 | 0.0248 | -- | -77.08 | -42.05 | -11.37 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Protara Therapeutics Inc's reporting currency: US Dollar USD
42.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 5.14m | 9.96% |
| Velan Capital Investment Management LPas of 31 Dec 2025 | 2.83m | 5.49% |
| Integral Health Asset Management LLCas of 31 Dec 2025 | 2.25m | 4.36% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 2.23m | 4.31% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.15m | 4.16% |
| Blackstone Alternative Asset Management LPas of 31 Dec 2025 | 1.91m | 3.70% |
| Sio Capital Management LLCas of 31 Dec 2025 | 1.72m | 3.32% |
| Catalio Capital Management LP (Investment Management)as of 31 Dec 2025 | 1.45m | 2.80% |
| Driehaus Capital Management LLCas of 31 Dec 2025 | 1.26m | 2.44% |
| UBS Securities LLCas of 31 Dec 2025 | 1.22m | 2.35% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
